Journal of Experimental & Clinical Cancer Research

CORRECTION

Open Access

Correction to: Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity

Tao Qin[1,2], Bai Li[1,2], Xiaoyue Feng[1,2], Shujun Fan[1,2], Lei Liu[3], Dandan Liu[1,2], Jun Mao[1,2], Ying Lu[4], Jinfeng Yang[5], Xiaotang Yu[1], Qingqing Zhang[1], Jun Zhang[6], Bo Song[1,2], Man Li[7*] and Lianhong Li[1,2*]

Correction to: J Exp Clin Cancer Res 37, 287 (2018) https://doi.org/10.1186/s13046-018-0934-9

Following publication of the original article [1], the authors identified minor errors in Fig. 6; specifically, in Fig. 6D, the incorrect transwell analysis image was used for the siUSP37#2 group without purmorphamine (bottom left image).

The corrected figure is provided here. The correction does not have any effect on the results or conclusions of the paper. The original article has been corrected.

Author details
[1]Department of Pathology, Dalian Medical University, Dalian 116044, People's Republic of China. [2]The Key Laboratory of Tumor Stem Cell Research of Liaoning Province, Dalian Medical University, Dalian 116044, People's Republic of China. [3]Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China. [4]Teaching Laboratory of Morphology, Dalian Medical University, Dalian 116044, People's Republic of China. [5]Department of Pathology, Xiangyang Central Hospital, Xiangyang 441000, People's Republic of China. [6]Department of Dean, Dalian Medical University, Dalian 116044, People's Republic of China. [7]Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, Liaoning Province, People's Republic of China.

Published online: 09 November 2021

Reference

1. Qin T, Li B, Feng X, et al. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity. J Exp Clin Cancer Res. 2018;37:287. https://doi.org/10.1186/s13046-018-0934-9.

The original article can be found online at https://doi.org/10.1186/s13046-018-0934-9.

*Correspondence: liman19890930@sina.com; lilianhong917@sina.com
[2] The Key Laboratory of Tumor Stem Cell Research of Liaoning Province, Dalian Medical University, Dalian 116044, People's Republic of China
[7] Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, Liaoning Province, People's Republic of China
Full list of author information is available at the end of the article



Fig. 6 USP37 knockdown inhibits stemness, cell invasion and EMT via Hedgehog signaling pathway in breast cancer. **a**, **b** MCF-7 cells were incubated with 0.5 μM purmorphamine for 24 and 48 h. **a** Hedgehog pathway constituents were examined via western blotting. GAPDH was examined as a loading control. $^{**}P < 0.01$, $^{***}P < 0.001$. **b** Immunofluorescence staining images of MCF-7 cells showed the expression of USP37 and Hedgehog pathway constituents. **c** Protein levels of USP37, Smo, Gli-1, ALDH1, OCT4, E-cadherin, N-cadherin, Snail1 as detected by western blotting after the NC siRNA group or the USP37 siRNA#2 group was treated with 0.5 μM purmorphamine for 48 h. GAPDH was examined as a loading control. $^{**}P < 0.01$, $^{***}P < 0.001$. **d** Cell invasion capacity of the NC siRNA group or the USP37 siRNA#2 group treated with 0.5 μM purmorphamine (Scale bar: 200 μm). **e** Spheroid formation capacity of MCF-7-ShScramble or MCF-7-shUSP37#2 cells treated with 0.5 μM purmorphamine (original magnification, 4×). **f** Immunofluorescence staining of E-cadherin and N-cadherin after the NC siRNA group or the USP37 siRNA#2 group treated with 0.5 μM purmorphamine for 48 h. (Scale bar: 50 μm). $^{*}P < 0.05$, $^{**}P < 0.01$